A high-throughput drug combination screen identifies an anti-glioma synergism between TH588 and PI3K inhibitors

A high-throughput drug combination screen identifies an anti-glioma synergism between TH588 and PI3K inhibitors

Abstract Background Glioblastoma multiforme (GBM) is the most common and lethal type of primary brain tumor. More than half of GBMs contain mutation(s) of PTEN/PI3K/AKT, making inhibitors targeting the PI3K pathway very attractive for clinical investigation. However, so far, PI3K/AKT/mTOR inhibitors...

Full description

Bibliographic Details
Main Authors: Zhen Chen, Chao Chen, Tingting Zhou, Chao Duan, Qianqian Wang, Xiaohui Zhou, Xia Zhang, Fangrong Wu, Yunfen Hua, Fan Lin
Format: Article
Language:English
Published: BMC 2020-07-01
Series:Cancer Cell International
Subjects:
Glioblastoma
Sensitivity index
PI3K
MTH1
TH588
Online Access:http://link.springer.com/article/10.1186/s12935-020-01427-0

Internet

http://link.springer.com/article/10.1186/s12935-020-01427-0

Similar Items